4L1 Lymphoma, B cell & sentinel (Case 4) neoplastic area CD20 4X | Sentinel & Steroid Rx Lesions | MYELIN (IMMUNE-MEDIATED)

Washington University Experience | MYELIN (IMMUNE-MEDIATED) | Sentinel & Steroid Rx Lesions | 4L1 Lymphoma, B cell & sentinel (Case 4) neoplastic area CD20 4X

4L1,2 The collections of malignant neoplastic B cells are highlighted by CD20 immunoreactivity (CD20 IHC)